GQ Targeting

Tipping Point Biosciences

This biotechnology company develops a drug discovery platform and small molecule therapies targeting dysfunctional DNA packaging for patients with cancer and neurodegenerative diseases.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

TwoStep Therapeutics

The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Aktis Oncology

This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.

Carrick Therapeutics

This biopharmaceutical company develops precision oncology therapies for patients with aggressive cancers, focusing on small molecules and inhibitors for solid tumours.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.